Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Preterm Infant Serum Proteomics Identifies Widespread Protein Reductions Preceding Bronchopulmonary Dysplasia

1 day ago 22

PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

In a comprehensive longitudinal investigation tracking circulating molecular profiles during the earliest days of neonatal life, researchers have identified eighty distinct serum proteins whose concentrations significantly diverge between extremely preterm infants who go on to develop bronchopulmonary dysplasia and those who do not. Published in Pediatric Research, the basic science investigation integrated three complementary proteomic technologies to profile blood serum drawn over the first two postnatal weeks from sixty-four premature infants born before thirty weeks of gestational age. The analysis revealed a striking biological pattern that challenges conventional assumptions regarding the condition: rather than exhibiting broad elevations in circulating pro-inflammatory signals, infants who subsequently received a diagnosis of moderate or severe bronchopulmonary dysplasia predominantly demonstrated widespread reductions across their circulating proteome. These notable deficits emerged most prominently on postnatal days three and seven, encompassing critical components of the insulin-like growth factor pathway, circulating immunoglobulins, vital signaling ligands, and protein signatures characteristic of several major blood cell lineages.

Bronchopulmonary dysplasia remains the most prevalent and challenging long-term morbidity affecting infants born prematurely, persisting as a leading contributor to extended hospitalizations, respiratory complications, and neurocognitive impairments. Across recent decades, advances in neonatal intensive care—including the administration of antenatal corticosteroids, the widespread adoption of exogenous surfactant replacement therapy, and the deliberate transition toward non-invasive or restrictive mechanical ventilation strategies—have dramatically elevated the survival rates of the most fragile premature newborns. However, as greater numbers of extremely low gestational age infants survive, the clinical and pathological presentation of the pulmonary condition has fundamentally transformed. Despite recognized clinical risk factors such as chorioamnionitis, low birth weight, and oxygen exposure, the underlying systemic molecular mechanisms driving this arrested developmental trajectory have remained incompletely defined.

To capture the temporal trajectory of molecular disruptions occurring prior to formal clinical diagnosis, the research team evaluated serial blood samples collected as part of the prospective PRIDICT-BPD cohort study conducted across two neonatal intensive care units at Amsterdam University Medical Centers in the Netherlands. The prospective study enrolled seventy preterm infants born below thirty weeks of gestation without major congenital malformations between November 2019 and October 2021. Following the exclusion of infants who died before thirty-six weeks postmenstrual age or whose caregivers withheld consent for extended analytical profiling, sixty-four infants formed the analytical cohort. Within this studied group, eighteen infants (twenty-eight percent) received a definitive diagnosis of bronchopulmonary dysplasia at thirty-six weeks postmenstrual age based on standardized physiological criteria establishing their requirement for supplemental oxygen or positive airway pressure support, with sixteen classified as severe cases and two classified as moderate. Infants developing the chronic pulmonary disorder exhibited lower mean gestational ages, lower birth weights, and a higher prevalence of small-for-gestational-age status alongside longer durations of mechanical ventilation.

Addressing the technical limitations that often hinder single-platform proteomic profiling in neonatal blood volumes, the investigators combined three advanced bioanalytical modalities to achieve broad coverage across distinct biological classes. Capillary and arterial serum samples collected at birth, postnatal day three, day seven, and day fourteen were processed through proximity extension assays, multiplexed targeted mass spectrometry, and untargeted data-independent acquisition liquid chromatography-tandem mass spectrometry. Concurrently, an in-house multiplexed targeted mass spectrometry assay quantified heavy and light isotope-labeled peptide ratios to establish absolute concentrations of circulating immunoglobulins. To measure broad plasma proteins, the team re-analyzed untargeted label-free mass spectrometry data using deep neural network identification algorithms in DIA-NN. Across these platforms, high quantitative concordance was documented for overlapping proteins, such as transforming growth factor beta-1 proprotein between Olink and untargeted mass spectrometry, and immunoglobulin heavy gamma chains across both mass spectrometry platforms, yielding six hundred and sixty-five reliably quantified proteins with at least seventy-five percent cohort data completeness.

Rigorous cross-sectional statistical comparisons between the infants who developed bronchopulmonary dysplasia and their unaffected counterparts identified eighty unique proteins with statistically significant alterations after Benjamini-Hochberg false discovery rate adjustments. Postnatal day three exhibited the greatest molecular divergence, with fifty-nine proteins significantly altered, followed by day seven, where forty proteins demonstrated significant differences. In contrast, only four proteins exhibited measurable shifts at birth, while eight proteins remained significantly altered by day fourteen. The overwhelmingly dominant quantitative feature across these identified differences was an unexpected decrease in protein abundance among infants who developed the chronic lung disease. Rather than mounting an exaggerated systemic inflammatory flood immediately following birth, infants who subsequently experienced disrupted lung architecture displayed depressed circulating levels across diverse molecular functional categories, including cell-surface glycoproteins, signaling ligands, extracellular matrix enzymes, humoral antibodies, and critical regulators of cellular growth and systemic vascular development.

A focused core of six specific circulating proteins demonstrated persistent, statistically significant reductions across every postnatal monitoring point evaluated from day three through day fourteen. This persistently suppressed group comprised Kit ligand (also known as stem cell factor or SCF), two distinct tumor necrosis factor ligand superfamily members—TRANCE (TNFSF11) and TWEAK (TNFSF12)—as well as total immunoglobulin heavy gamma, together with the specific subclasses IGHG1 and IGHG3. Kit ligand functions as an indispensable regulator of hematopoiesis, endothelial cell migration, and vascular assembly; previous experimental hyperoxia models in neonatal rodents demonstrated that exogenous administration of this factor successfully restored alveolarization and vascular architecture. The parallel decline in TRANCE and TWEAK, which regulate tissue repair and bone morphogenesis, occurred rapidly near day three in affected infants while remaining stable in control infants. Concurrently, the progressive reduction in maternal immunoglobulin G subclasses suggests accelerated systemic antibody clearance or hyperconsumption during the initial two postnatal weeks, potentially compounding the infant’s susceptibility to opportunistic systemic infections.

A small cluster containing interleukin-10, an established anti-inflammatory mediator, and chemokine ligand CCL19 showed a transient, significant increase at day three in infants who developed bronchopulmonary dysplasia, inversely correlating with the three remaining cytokine clusters. A second cluster, featuring TRAIL, exhibited marked reductions on days three and seven before normalizing toward day fourteen. The third cluster, including T-cell surface markers CD5 and CD6, declined more rapidly in infants developing the disease. The largest cluster, containing thirteen mediators including interleukin-1 alpha, vascular endothelial growth factor A, and transforming growth factor beta-1, increased gradually over time in healthy infants but remained persistently depressed in infants developing the condition. Intriguingly, classical systemic inflammatory markers routinely monitored in clinical medicine—including C-reactive protein, lipopolysaccharide-binding protein, interleukin-6, interleukin-8, and tumor necrosis factor alpha—showed no statistically significant differences between the two clinical outcome cohorts during the first postnatal week.

The multi-proteomic investigation also exposed pronounced disruptions within the circulating insulin-like growth factor hormonal axis, a regulatory system heavily implicated in postnatal somatic growth and microvascular lung development. While direct mass spectrometry quantification of free insulin-like growth factor-1 fell below analytical detection thresholds in the micro-volume serum samples, downstream components of the ternary hormonal regulatory complex showed marked disturbances. Specifically, insulin-like growth factor-binding complex acid labile subunit (IGFALS) showed significant reductions at both postnatal day three and day seven among infants developing bronchopulmonary dysplasia. Because circulating IGFALS forms an essential high-molecular-weight ternary complex with insulin-like growth factor-1 and insulin-like growth factor-binding protein 3 that shields the active hormone from rapid enzymatic clearance, its suppression offers a molecular explanation for the low circulating growth factor availability historically documented in vulnerable infants. Conversely, insulin-like growth factor-binding protein 1 (IGFBP1), which competes for free growth factor and modulates its bioavailability, demonstrated significant elevation on day seven in the affected group.

Bioinformatic pathway and cell-type enrichment analyses demonstrated that many of the down-regulated circulating proteins did not originate from isolated endocrine sources, but represented circulating cellular signatures derived from myeloid, lymphoid, and megakaryocytic lineages. Gene expression mapping against established neonatal blood cell transcriptomic reference databases confirmed strong representations of neutrophil-associated enzymes, including matrix metalloproteinase-9 (MMP9) and lysosome-associated membrane glycoprotein 2 (LAMP2), alongside platelet-specific alpha granule proteins such as pro-platelet basic protein (PPBP), platelet factor 4 (PF4), and integrin alpha-IIb (ITGA2B). In infants who developed bronchopulmonary dysplasia, these cell-derived proteins showed profound nadirs at day three, followed by a gradual normalization toward day fourteen.

While providing a rich multi-system catalog of early biological shifts, the study authors emphasize several critical methodological boundaries that must contextualize their proof-of-concept findings. Because of the relatively small cohort of sixty-four neonates, statistical analyses could not fully adjust for major perinatal confounders, including the significantly higher frequency of small-for-gestational-age infants and maternal infection exposures among those developing chronic lung impairment. For example, circulating adiponectin (ADIPOQ) was persistently depressed in affected infants, an observation that may directly reflect the metabolic consequences of intrauterine fetal growth restriction rather than an isolated pulmonary pathogenesis. Furthermore, analytical discrepancies between targeted and untargeted mass spectrometry for mucosal immunoglobulin heavy constant alpha 1 (IGHA1), alongside attrition at day twenty-eight due to clinical discharge or early mortality, underscore the necessity for caution. Future translational validation will require larger multicenter prospective cohorts incorporating paired maternal, umbilical cord, and serial postnatal biospecimens to establish whether these early protein depressions can serve as actionable clinical targets for therapeutic preservation.

Subject of Research: Longitudinal multi-proteomic analysis of early serum protein alterations in preterm infants developing bronchopulmonary dysplasia.

Article Title: Exploring the pathogenesis underlying development of bronchopulmonary dysplasia in preterm infants using serum multi-proteomics

Article References: Smit, E. R., Langerhorst, P., Romijn, M., van Tuyl, M., Rotteveel, J., Teunissen, C. E., van Kaam, A. H., Finken, M. J. J., Onland, W., & van den Biggelaar, M. (2026). Exploring the pathogenesis underlying development of bronchopulmonary dysplasia in preterm infants using serum multi-proteomics. Pediatric Research. https://doi.org/10.1038/s41390-026-05542-y

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05542-y

Keywords: bronchopulmonary dysplasia, preterm infants, proteomics, neonatal intensive care, serum biomarkers, insulin-like growth factor, immunoglobulins, cytokines, IGFALS, IGFBP1, SCF, TRANCE, TWEAK, platelet basic protein, targeted mass spectrometry, untargeted mass spectrometry, proximity extension assay

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway